April 2025

FormularyDecisions Connection Newsletter

Browse new features, discover platform releases, learn about upcoming events, and stay up to date on all the latest insights.

In this month's Connection newsletter:

 

Parkinson’s Disease Awareness Month

April is Parkinson’s disease awareness month, and you can use FormularyDecisions to connect you to resources to help better understand the disease state and treatment landscape.

Parkinson's disease is the second most common age-related neurodegenerative condition diagnosed in North America and is commonly found in middle-aged and older adults.1,2 The diagnosis of Parkinson's disease occurs in nearly 90,000 individuals per year for those aged 65 and older.2 The disease is primarily identified by motor-related symptoms such as tremors, stiffness, and slowed movement, which significantly impact quality of life.3 Currently, there is no cure for Parkinson’s disease, but advancements in disease management are helping to improve patient outcomes through early diagnosis and innovative therapies.

Utilize our resources below to access the latest information:

Utilize the disease page and drug class review to access the latest information on Parkinson’s disease. A sample of Metasearch Results articles from the Parkinson’s disease page is included below.
Disease Page

hcdm

 

From the Parkinson's disease page, explore related products and links from third-party resources and publications in the Metasearch Results.
Drug Class Review

hcdm

 

Create a custom Drug Class Review table on FormularyDecisions to help explore the therapeutic area and drugs.


Here’s a sample of Metasearch Results articles available across various product and disease pages on FormularyDecisions that shed light on the science and advances in Parkinson’s disease treatment:  

 

This announcement is an advertisement paid for by Vertex Pharmaceuticals Incorporated. FormularyDecisions is not providing a product recommendation. Readers should review all available materials related to the product and indication discussed herein before making any decision related to the purchase or use of the product. Any questions about such products must be directed to the biopharma company.

 

 

Reconnecting after AMCP Annual 2025

We enjoyed connecting with you at AMCP Annual last week! Thank you to all who stopped by the Cencora booth at the expo hall, connected with us at the FormularyDecisions kiosk, and attended our networking event, “Houston! We Have a Solution.”

During the event, we highlighted some of the newest additions to FormularyDecisions, including our transition to Zoom webinars, the visibility of approved vs unapproved eDossiers, and using the “follow” feature to stay up-to-date on the latest product information.

If you were unable to join us in person and would like to learn more about the different resources available to you on FormularyDecisions, we invite you to schedule a demo with one of our clinical pharmacists. 
 

Explore the latest Resource Center files

Several biopharma companies recently posted new or updated content in their Resource Centers, including product briefs, clinical overviews, publications, posters, and more! Many of these resources contain consolidated, up-to-date product information that you can include in your upcoming product reviews. See below for Resource Center files posted in the last 3 months. Click here to view a list of all products with Resource Center files. 

 


Product namea
Resource Center document description(s)

ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor)10

Prescribing information, important safety information, and WAC pricing

CARVYKTI® (ciltacabtagene autoleucel)11

Patient brochure and interactive leave-behind

DARZALEX® (daratumumab)12

Reimbursement guide, dosing and administration guide, and digital flashcards

DOVATO (dolutegravir and lamivudine)13

Efficacy and safety, WAC pricing, and head-to-head clinical data

GOMEKLI™ (mirdametinib)14

Prescribing information, ICD-10-CM flashcard, EHR guides, product fact sheet, ordering guide, potential UM document, clinical trial publication, and value presentation

JAKAFI® (ruxolitinib)15

Value propositions, AJMC clinical brief publication, and cost comparisons

JOURNAVX™ (suzetrigine)16

Health system economic calculator and user guide, pricing fact sheet, P&T request form, product fact sheet, product monograph, formulary kit, and value proposition presentations

MONJUVI® (tafasitamab-cxix)17

Payer value proposition presentation and RWE digital brochure

NEXLIZET® (bempedoic acid and ezetimibe)18

Budget impact model, PA mini checklist, ICER report, and real-world effectiveness study

NUBEQA® (darolutamide)19

Phase II trial published in Journal of Clinical Oncology®

OPZELURA® (ruxolitinib)20

Retrospective claims analysis

RYBREVANT® (amivantamab-vmjw)21

Update results from a phase 2 study, NCCN® guidelines, head-to-head clinical data, and information on ongoing clinical trials

SAPHNELO® (anifrolumab-fnia)22

Buy-and-bill reference guide, coding resource, important safety information, phase 3 clinical trial results, and retrospective study data

SKYRIZI® (risankizumab-rzaa)23

Medical value on a portfolio of products and head-to-head clinical data

TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)24

Cost analysis study results, real-world safety and effectiveness study, how-supplied resource, WAC pricing, prescribing information, and important safety information

TYVASO DPI® (treprostinil)25

Long-term safety, efficacy, and patient-reported outcomes

Key: AJMC – American Journal of Managed Care; EHR – electronic health record; ICD-10-CM – International Classification of Diseases, 10th Revision, Clinical Modification; ICER – Institute for Clinical and Economic Review; NCCN – National Comprehensive Cancer Network; PA – prior authorization; P&T – Pharmacy & Therapeutics; RWE – real-world evidence; UM – utilization management; WAC – wholesale acquisition cost.

 

Pre-approval product nameb
Resource Center document description(s)

MSP-2017 (etripamil)

Phase 3 study results and healthcare resource utilization

mRNA-1283 (SARS-CoV-2/Covid-19 vaccine)

Burden, candidate product information, efficacy, and healthcare economics

UGN-102 (mitomycin)

PIE presentation

Key: PIE – pre-approval information exchange.

 


 

Upcoming webinars

Stay current with the latest sessions by registering for upcoming webinars and accessing past recordings.

AMCP PIE Webinar

An Investigational RNA-Targeted Long-Term Prophylactic Medicine for Hereditary Angioedema (HAE)b

Date: Tuesday, May 13, 2025
Time: 2:00-3:00pm ET

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

This PIE webinar is sponsored by Ionis Pharmaceuticals, Inc. The content of the webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP or FormularyDecisions. FormularyDecisions is proud to partner with AMCP to enable information sharing between healthcare decision-makers and biopharma companies.

Click below for webinar details and to register:

AMCP PIE Webinar

Pediatric Myopia Progression in the US: Addressing the Disease and Unmet Need Behind an Emerging Epidemicb

Date: Wednesday, May 21, 2025
Time: 2:00-3:00pm ET

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

This PIE webinar is sponsored by Sydnexis. The content of the webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP or FormularyDecisions. FormularyDecisions is proud to partner with AMCP to enable information sharing between healthcare decision-makers and biopharma companies.

Click below for webinar details and to register:

 

Share with your peers

Know someone who could benefit from access to information on over 3,900 pipeline and FDA-approved products? Take a few seconds and use our email template to inform your peers or colleagues about FormularyDecisions.

 

Learn something new

Equip your clinical team with a resource that streamlines the search for relevant product information. Schedule a demo and ensure your team is leveraging all that FormularyDecisions has to offer.

 

Our dedicated team is ready to assist!

Need assistance logging into FormularyDecisions, interesting in referring a peer or colleague, or looking to schedule a personalized refresher demo – we're here to help!

 

References: 

1. Luo Y, Qiao L, Li M, Wen X, Zhang W, Li X. Global, regional, national epidemiology and trends of Parkinson's disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Front Aging Neurosci. 2025;16:1498756.  
2. Willis AW, Roberts E, Beck JC, et al. Incidence of Parkinson disease in North America. NPJ Parkinsons Dis. 2022;8(1):170. 
3. Parkinson’s disease: causes, symptoms, and treatments. National Institute of Health. April 14, 2022. Accessed February 18, 2025. https://www.nia.nih.gov/health/parkinsons-disease/parkinsons-disease-causes-symptoms-and-treatments 
4. Neilson LE, Reavis KM, Wiedrick J, Scott GD. Hearing loss, incident Parkinson disease, and treatment with hearing aids. JAMA Neurol. 2024;81(12):1295-1303. doi:10.1001/jamaneurol.2024.3568 https://jamanetwork.com/journals/jamaneurology/article-abstract/2824569?resultClick=1 
5. Erickson CM, Wexler A, Largent EA. Digital Biomarkers for Neurodegenerative Disease. JAMA Neurol. 2025;82(1):5-6. doi:10.1001/jamaneurol.2024.3533 
6. Chou K. Diagnosis and differential diagnosis of Parkinson disease. UpToDate.com. Literature review current through: Feb 2025. Accessed March 31, 2025. https://www.uptodate.com/contents/diagnosis-and-differential-diagnosis-of-parkinson-disease?search=parkinson%27s+disease+%28pd%29+parkinson%27s+disease+%28pd%29&source=search_result&selectedTitle=4%7E150&usage_type=default 
7. Artificial intelligence in molecular imaging: Predicting Parkinson's risk in REM sleep behavior disorder (NUK-RBD). ClinicalTrials.gov ID: NCT06629207. Last update posted: November 8, 2024. Accessed March 31, 2025. https://clinicaltrials.gov/study/NCT06629207?term=parkinson%27s%20disease%20(pd)%20OR%20parkinson%27s%20disease%20(pd) 
8. Rodnitzky R. Cognitive impairment and dementia in Parkinson disease. UpToDate.com. Literature review current through: Feb 2025. Accessed March 31, 2025. https://www.uptodate.com/contents/cognitive-impairment-and-dementia-in-parkinson-disease?search=parkinson%27s+disease+%28pd%29+parkinson%27s+disease+%28pd%29&source=search_result&selectedTitle=1%7E150&usage_type=default 
9. Electrophysiological signature of mild cognitive impairment and its relationship with Parkinson's disease: a high-density EEG investigation (MMCI). ClinicalTrials.gov ID: NCT06640673. Last update posted October 15, 2024. Accessed March 31, 2025. https://clinicaltrials.gov/study/NCT06640673?term=parkinson%27s%20disease%20(pd)%20OR%20parkinson%27s%20disease%20(pd) 
10. Alyftrek. Prescribing information. Vertex Pharmaceuticals Incorporated; 2024. Accessed March 31, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218730s000lbl.pdf 
11. Carvykti. Prescribing information. Janssen Biotech, Inc.; 2024. Accessed March 31, 2025. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi.pdf
12. Darzalex. Prescribing information. Janssen Biotech, Inc.; 2024. Accessed March 31, 2025. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf
13. Dovato. Prescribing information. ViiV Healthcare; 2024. Accessed March 31, 2025. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Dovato/pdf/DOVATO-PI-PIL.PDF 
14. Gomekli. Prescribing information. SpringWorks Therapeutics, Inc.; 2025. Accessed March 31, 2025. https://springworkstx.com/wp-content/uploads/2025/02/GOMEKLI-USPI-Final-Feb-11-2025_.pdf 
15. Jakafi. Prescribing information. Incyte Corporation; 2023. Accessed March 31, 2025. https://www.jakafi.com/jakafi-prescribing-information
16. Journavx. Prescribing information. Vertex Pharmaceuticals Incorporated; 2025. Accessed March 31, 2025. https://pi.vrtx.com/files/uspi_suzetrigine.pdf 
17. Monjuvi. Prescribing information. Incyte Corporation; 2024. Accessed March 31, 2025. https://www.monjuvi.com/pi/monjuvi-pi.pdf
18. Nexlizet. Prescribing information. Esperion Therapeutics, Inc.; 2024. Accessed March 31, 2025. https://pi.esperion.com/nexlizet/nexlizet-pi.pdf 
19. Nubeqa. Prescribing information. Bayer HealthCare Pharmaceuticals; 2023. Accessed March 31, 2025. https://labeling.bayerhealthcare.com/html/products/pi/Nubeqa_PI.pdf?inline=- 
20. Opzelura. Prescribing information. Incyte Corporation; 2024. Accessed March 31, 2025. https://www.opzelura.com/opzelura-prescribing-information 
21. Rybrevant. Prescribing information. Janssen Biotech, Inc.; 2024. Accessed March 31, 2025. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf
22. Saphnelo. Prescribing information. AstraZeneca Pharmaceuticals LP; 2024. Accessed March 31, 2025. https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/44b6985c-8268-46b1-ba3e-2bb43bfd4d4c/44b6985c-8268-46b1-ba3e-2bb43bfd4d4c_viewable_rendition__v.pdf 
23. Skyrizi. Prescribing information. AbbVie Inc.; 2024. Accessed March 31, 2025. https://www.rxabbvie.com/pdf/skyrizi_pi.pdf
24. Trikafta. Prescribing information. Vertex Pharmaceuticals Incorporated; 2023. Accessed March 31, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212273s009lbl.pdf
25. Tyvaso DPI. Prescribing information. United Therapeutics Corp.; 2024. https://www.tyvaso.com/pdf/TYVASO-DPI-PI.pdf 

 
a The material is being shared to inform you of the availability of information on FormularyDecisions. In providing this information, FormularyDecisions is not promoting any products mentioned, making claims about risks or benefits, or otherwise recommending any product in general or for any patient or formulary. For complete information about the indications, risks, and benefits of any product, please consult appropriate clinical and safety information, including the complete product label and important safety information. All prescribing decisions and/or coverage decisions should be made independently by individuals with appropriate experience in reliance on their independent judgement.   
 
b The products listed are in the clinical evaluation stage and have not been approved for use by the FDA. The safety and efficacy of these products have not been established. FormularyDecisions is providing this information to alert you to the status of this product and is not promoting this product generally or otherwise recommending this product for use in the treatment of any disease or inclusion on any formulary for which it has not yet been approved. Any questions about such products must be directed to the biopharma companies. The availability of this product information follows the guidance outlined in the Pre-approval Information Exchange Act of 2022 (Section 810 of H.R. 7667).  

FormularyDecisions is owned and operated by Cencora Global Consulting Services US Corporation, which is a subsidiary (whether directly or indirectly) of Cencora, Inc. a global pharmaceutical sourcing and distribution services company. 
 
The contents of this communication are non-promotional and intended exclusively for healthcare decision-makers, formulary committees, and other similar entities responsible for selecting healthcare products for coverage or reimbursement. Do not forward this communication. FormularyDecisions strongly encourages our members to review all available information about a particular product, including but not limited to the product label, and to rely on their experience and expertise in making decisions about coverage or prescribing.